[go: up one dir, main page]

DK1181024T3 - Anvendelse af glycosaminoglycaner til behandling af senil demens - Google Patents

Anvendelse af glycosaminoglycaner til behandling af senil demens

Info

Publication number
DK1181024T3
DK1181024T3 DK00925281T DK00925281T DK1181024T3 DK 1181024 T3 DK1181024 T3 DK 1181024T3 DK 00925281 T DK00925281 T DK 00925281T DK 00925281 T DK00925281 T DK 00925281T DK 1181024 T3 DK1181024 T3 DK 1181024T3
Authority
DK
Denmark
Prior art keywords
treatment
senile dementia
glycosaminoglycans
alzheimer
ictus
Prior art date
Application number
DK00925281T
Other languages
Danish (da)
English (en)
Inventor
Umberto Cornelli
Ambrosi Luigi De
Israel Hanin
Jawed Fareed
John Lee
Stanley Lorens
Ronald F Mervis
Original Assignee
Umberto Cornelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umberto Cornelli filed Critical Umberto Cornelli
Application granted granted Critical
Publication of DK1181024T3 publication Critical patent/DK1181024T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK00925281T 1999-05-14 2000-05-12 Anvendelse af glycosaminoglycaner til behandling af senil demens DK1181024T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
PCT/EP2000/004311 WO2000069444A1 (en) 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia

Publications (1)

Publication Number Publication Date
DK1181024T3 true DK1181024T3 (da) 2005-06-13

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00925281T DK1181024T3 (da) 1999-05-14 2000-05-12 Anvendelse af glycosaminoglycaner til behandling af senil demens

Country Status (22)

Country Link
US (1) US6979680B1 (ru)
EP (1) EP1181024B1 (ru)
JP (1) JP2002544233A (ru)
KR (1) KR100711142B1 (ru)
CN (1) CN1178667C (ru)
AT (1) ATE288761T1 (ru)
AU (1) AU764743C (ru)
CA (1) CA2373975A1 (ru)
CZ (1) CZ20014092A3 (ru)
DE (1) DE60018061T2 (ru)
DK (1) DK1181024T3 (ru)
ES (1) ES2237425T3 (ru)
HK (1) HK1039903B (ru)
HU (1) HUP0201100A3 (ru)
IL (1) IL146458A0 (ru)
IT (1) IT1312107B1 (ru)
NO (1) NO328902B1 (ru)
PL (1) PL198016B1 (ru)
PT (1) PT1181024E (ru)
RU (1) RU2248800C2 (ru)
WO (1) WO2000069444A1 (ru)
ZA (1) ZA200109331B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
BRPI0620637A2 (pt) 2005-12-22 2011-11-16 Neurochem Int Ltd uso de compostos na preparação de medicamentos para a prevenção ou o tratamento de nefropatia diabética, complicação de desordem renal e dislipidemia, redução dos nìveis de lipìdeos e ácido úrico no soro, e aumento do clearance de creatinina e da função renal
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
JP5450602B2 (ja) 2008-05-22 2014-03-26 エゴロヴィチ バラキン、ウラジミール シンクロトロンによって加速された荷電粒子を用いて腫瘍を治療する腫瘍治療装置
CN102113419B (zh) 2008-05-22 2015-09-02 弗拉迪米尔·叶戈罗维奇·巴拉金 多轴带电粒子癌症治疗方法和装置
AU2009249867B2 (en) 2008-05-22 2013-05-02 Vladimir Yegorovich Balakin Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system
US8766217B2 (en) 2008-05-22 2014-07-01 Vladimir Yegorovich Balakin Multi-field charged particle cancer therapy method and apparatus
CA2754345C (en) 2009-03-04 2015-06-23 Zakrytoe Aktsionernoe Obshchestvo Protom Multi-field charged particle cancer therapy method and apparatus
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2675993T3 (es) 2011-10-14 2018-07-16 Centre National De La Recherche Scientifique Procedimiento de diagnóstico, pronóstico o tratamiento de enfermedades neurodegenerativas
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
US4769696A (en) * 1986-05-01 1988-09-06 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
IT1205042B (it) 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1240615B (it) * 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale

Also Published As

Publication number Publication date
EP1181024B1 (en) 2005-02-09
ZA200109331B (en) 2002-08-28
NO328902B1 (no) 2010-06-14
JP2002544233A (ja) 2002-12-24
WO2000069444A1 (en) 2000-11-23
HK1039903B (zh) 2005-08-26
CN1350459A (zh) 2002-05-22
PL198016B1 (pl) 2008-05-30
KR20020005033A (ko) 2002-01-16
RU2248800C2 (ru) 2005-03-27
PT1181024E (pt) 2005-06-30
CZ20014092A3 (cs) 2002-04-17
AU4405200A (en) 2000-12-05
AU764743C (en) 2004-03-18
NO20015544L (no) 2002-01-14
EP1181024A1 (en) 2002-02-27
IT1312107B1 (it) 2002-04-04
ATE288761T1 (de) 2005-02-15
DE60018061T2 (de) 2006-04-13
NO20015544D0 (no) 2001-11-13
ITMI991066A1 (it) 2000-11-14
CN1178667C (zh) 2004-12-08
CA2373975A1 (en) 2000-11-23
HUP0201100A2 (hu) 2002-07-29
KR100711142B1 (ko) 2007-04-24
IL146458A0 (en) 2002-07-25
PL352070A1 (en) 2003-07-28
DE60018061D1 (de) 2005-03-17
US6979680B1 (en) 2005-12-27
ES2237425T3 (es) 2005-08-01
HUP0201100A3 (en) 2003-03-28
AU764743B2 (en) 2003-08-28
HK1039903A1 (en) 2002-05-17

Similar Documents

Publication Publication Date Title
DK1181024T3 (da) Anvendelse af glycosaminoglycaner til behandling af senil demens
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
WO2000047568A3 (en) 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
UA48946C2 (ru) Translated By PlajАРИЛАЛКИЛДИАЗИНОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ
TR200001264T2 (tr) Alzheimer hastalığının antermotem teşhisi için bileşikler.
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2006040451A2 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
PL346143A1 (en) Tan-1057 derivatives
WO2001083449A3 (en) Rigid pyrrolidone modulators of pkc
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
HUP0203161A2 (hu) Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.